Biomarin Pharmaceutical Inc (BMRN) 80.56 $BMRN
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.43 (+0.88), GE: 25.66 (-0.22), BMRN: 80.56 (-1.49), IDXX: 141.95 (-0.64), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:54AM CDT
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue?
BMRN: 80.56 (-1.49)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 99.55 (-1.63), MACK: 9.19 (-0.16), BMRN: 80.56 (-1.49), ILMN: 188.88 (-1.77)
The 5 Most Expensive Drugs in the World
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 26, 11:21AM CDT
Source: StockMonkeys.com via Flickr . Whether you're prepared for it or not, prescription drug prices remain on the rise within the United States. Overall medical cost inflation may be at a multi-decade low in the U.S., but that doesn't seem to...
MNK: 93.01 (-0.73), VRTX: 109.91 (-4.16), BMRN: 80.56 (-1.49), SHPG: 196.45 (-1.35), ALXN: 190.49 (-1.71)
After Yesterday's Rally of 8.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Oct 24, 4:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $75.40 to a high of $81.83. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high of $75.86 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.56 (-1.49)
BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:12PM CDT
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected third-quarter 2014 loss of 16 cents per share.
MDVN: 99.55 (-1.63), BMRN: 80.56 (-1.49), ILMN: 188.88 (-1.77), SNY: 45.22 (-2.85)
BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 7:38PM CDT
Every biotech dreams of having a blockbuster drug with annual sales higher than $1 billion. But ultra-orphan-drugmaker BioMarin Pharmaceuticals has a more realistic short-term goal: have $1 billion in sales for biotech's basket of five drugs. ...
BMRN: 80.56 (-1.49), SNY: 45.22 (-2.85)
BioMarin Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 3:02PM CDT
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales
BMRN: 80.56 (-1.49)
Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:30PM CDT
BioMarin is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 109.91 (-4.16), BMRN: 80.56 (-1.49), LGND: 53.33 (+1.44), TEVA: 54.49 (-0.31)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 80.56 (-1.49), ALNY: 91.53 (-2.72), SRPT: 15.19 (+0.07), SHPG: 196.45 (-1.35), NPSP: 27.21 (-0.91)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 80.56 (-1.49), LXRX: 1.43 (+0.02), AMGN: 158.88 (+1.69), REGN: 387.70 (-10.19), EXEL: 1.70 (-0.05)
Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's "Roof Leaker" Stock
at The Street - Tue Oct 14, 9:13AM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
BMRN: 80.56 (-1.49)
BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
GlobeNewswire - Wed Oct 08, 7:35AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 23, at 4:30 p.m. ET to discuss third quarter 2014 financial results and provide a general business update.
BMRN: 80.56 (-1.49)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 80.56 (-1.49), ARQL: 1.17 (+0.03), BMY: 54.16 (-0.04), GSK: 45.08 (-0.02), ONTY: 1.84 (-0.07), ECYT: 5.96 (+0.01), MRK: 56.20 (+0.35), AEZS: 1.11 (-0.06), GALE: 2.14 (+0.08), NVS: 91.31 (-1.04), XLRN: 34.74 (-1.09), KPTI: 39.81 (+1.78)
Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug
at The Street - Tue Sep 30, 6:20AM CDT
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
MNK: 93.01 (-0.73), BMRN: 80.56 (-1.49), CPRX: 2.71 (-0.01), RTRX: 9.50 (+0.16)
Critical Alerts For Westport Innovations, Royal Bank of Scotland Group PLC ADS, Magnum Hunter Resources Corp, BioMarin Pharmaceutical and Allergan Released By InvestorsObserver
PR Newswire - Fri Sep 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for WPRT, RBS, MHR, BMRN and AGN.
AGN: 186.77 (+4.17), WPRT: 6.08 (-0.20), MHR: 4.71 (+0.09), BMRN: 80.56 (-1.49), RBS: 11.57 (-0.12)
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:24PM CDT
The FDA received paragraph IV certification notice pertaining to BioMarin's (BMRN) Kuvan.
ENDP: 65.65 (-0.93), BMRN: 80.56 (-1.49), AMGN: 158.88 (+1.69)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 3.64%
Comtex SmarTrend(R) - Wed Sep 24, 4:33PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $69.17 to a high of $72.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $70.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.56 (-1.49)
FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets
GlobeNewswire - Wed Sep 24, 4:21PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and Drug Administration (FDA) in connection with an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of KUVAN (sapropterin dihydrochloride) Tablets, although it has not yet received notice of the certification.
BMRN: 80.56 (-1.49)
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Tue Sep 23, 7:00AM CDT
- Jefferies Gene Therapy Summit on September 30 in Boston
BMRN: 80.56 (-1.49)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.43 (+0.88), GE: 25.66 (-0.22), BMRN: 80.56 (-1.49), IDXX: 141.95 (-0.64), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:54AM CDT
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue?
BMRN: 80.56 (-1.49)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 99.55 (-1.63), MACK: 9.19 (-0.16), BMRN: 80.56 (-1.49), ILMN: 188.88 (-1.77)
The 5 Most Expensive Drugs in the World
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 26, 11:21AM CDT
Source: StockMonkeys.com via Flickr . Whether you're prepared for it or not, prescription drug prices remain on the rise within the United States. Overall medical cost inflation may be at a multi-decade low in the U.S., but that doesn't seem to...
MNK: 93.01 (-0.73), VRTX: 109.91 (-4.16), BMRN: 80.56 (-1.49), SHPG: 196.45 (-1.35), ALXN: 190.49 (-1.71)
After Yesterday's Rally of 8.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Oct 24, 4:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $75.40 to a high of $81.83. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high of $75.86 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.56 (-1.49)
BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:12PM CDT
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected third-quarter 2014 loss of 16 cents per share.
MDVN: 99.55 (-1.63), BMRN: 80.56 (-1.49), ILMN: 188.88 (-1.77), SNY: 45.22 (-2.85)
BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 7:38PM CDT
Every biotech dreams of having a blockbuster drug with annual sales higher than $1 billion. But ultra-orphan-drugmaker BioMarin Pharmaceuticals has a more realistic short-term goal: have $1 billion in sales for biotech's basket of five drugs. ...
BMRN: 80.56 (-1.49), SNY: 45.22 (-2.85)
BioMarin Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 3:02PM CDT
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales
BMRN: 80.56 (-1.49)
Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:30PM CDT
BioMarin is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 109.91 (-4.16), BMRN: 80.56 (-1.49), LGND: 53.33 (+1.44), TEVA: 54.49 (-0.31)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 80.56 (-1.49), ALNY: 91.53 (-2.72), SRPT: 15.19 (+0.07), SHPG: 196.45 (-1.35), NPSP: 27.21 (-0.91)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 80.56 (-1.49), LXRX: 1.43 (+0.02), AMGN: 158.88 (+1.69), REGN: 387.70 (-10.19), EXEL: 1.70 (-0.05)
Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's "Roof Leaker" Stock
at The Street - Tue Oct 14, 9:13AM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
BMRN: 80.56 (-1.49)
BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
GlobeNewswire - Wed Oct 08, 7:35AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 23, at 4:30 p.m. ET to discuss third quarter 2014 financial results and provide a general business update.
BMRN: 80.56 (-1.49)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 80.56 (-1.49), ARQL: 1.17 (+0.03), BMY: 54.16 (-0.04), GSK: 45.08 (-0.02), ONTY: 1.84 (-0.07), ECYT: 5.96 (+0.01), MRK: 56.20 (+0.35), AEZS: 1.11 (-0.06), GALE: 2.14 (+0.08), NVS: 91.31 (-1.04), XLRN: 34.74 (-1.09), KPTI: 39.81 (+1.78)
Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug
at The Street - Tue Sep 30, 6:20AM CDT
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
MNK: 93.01 (-0.73), BMRN: 80.56 (-1.49), CPRX: 2.71 (-0.01), RTRX: 9.50 (+0.16)
Critical Alerts For Westport Innovations, Royal Bank of Scotland Group PLC ADS, Magnum Hunter Resources Corp, BioMarin Pharmaceutical and Allergan Released By InvestorsObserver
PR Newswire - Fri Sep 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for WPRT, RBS, MHR, BMRN and AGN.
AGN: 186.77 (+4.17), WPRT: 6.08 (-0.20), MHR: 4.71 (+0.09), BMRN: 80.56 (-1.49), RBS: 11.57 (-0.12)
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:24PM CDT
The FDA received paragraph IV certification notice pertaining to BioMarin's (BMRN) Kuvan.
ENDP: 65.65 (-0.93), BMRN: 80.56 (-1.49), AMGN: 158.88 (+1.69)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 3.64%
Comtex SmarTrend(R) - Wed Sep 24, 4:33PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $69.17 to a high of $72.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $70.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.56 (-1.49)
FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets
GlobeNewswire - Wed Sep 24, 4:21PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and Drug Administration (FDA) in connection with an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of KUVAN (sapropterin dihydrochloride) Tablets, although it has not yet received notice of the certification.
BMRN: 80.56 (-1.49)
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Tue Sep 23, 7:00AM CDT
- Jefferies Gene Therapy Summit on September 30 in Boston
BMRN: 80.56 (-1.49)
